This episode of The Space In Between centers on cancer—a topic that touches nearly everyone and, crucially, reminds us of our shared humanity. When a loved one receives a diagnosis, compassion cuts through ideology: neighbors cook meals, coworkers donate PTO, communities fundraise. Fighting cancer becomes a common cause that unites us in hope. Host Leigh Morgan is joined by Dr. Nancy Davidson—renowned breast cancer oncologist, translational researcher, and executive vice president/chief academic officer at Fred Hutch Cancer Center—to offer a clear-eyed, optimistic update on where oncology stands and where it’s headed.
Where We Are Now: Innovation with Results
Decades of laboratory and clinical research—much of it publicly funded—are paying off. Targeted therapies and immunotherapies are improving outcomes across multiple cancers, while advances in surgery and radiation mean many patients receive less invasive, more precise care. Checkpoint inhibitors (like pembrolizumab) have transformed treatment for cancers with high DNA damage such as melanoma and some lung cancers, and cellular therapies (CAR-T) are delivering durable remissions in several blood cancers, with efforts underway to extend benefits to solid tumors. The net effect: steady declines in cancer mortality over recent decades and a growing sense of warranted optimism.
Cancer Isn’t One Disease: Precision in Practice
A core theme is specificity. Cancer arises in different organs and is driven by distinct molecular pathways; treatment works best when it matches the biology. In breast cancer, for example, hormone receptor–positive tumors respond to therapies that block estrogen and progesterone signaling, while HER2-driven tumors benefit from HER2-targeted drugs. In lung cancer, EGFR mutations point to effective oral targeted therapies. This precision approach helps patients get the treatments most likely to work—and avoid those that won’t.
Prevention and Early Detection: The Power We Control
Roughly 30–40% of cancers are preventable through environmental and lifestyle changes. The biggest levers include eliminating tobacco use; addressing obesity; and using cancer-prevention vaccines such as hepatitis B (to reduce liver cancer) and HPV (to reduce cervical and many head-and-neck cancers) for boys and girls alike. Coupled with access to primary care and appropriate screening, prevention and early detection can save lives long before a patient reaches the oncology clinic.
Headwinds Ahead: Funding Cuts, Equity and Access
Outcomes are shaped by biology and by context—family history and genetics, socioeconomic conditions, geography, and environmental exposures. Some communities (e.g., Alaska Native populations for colorectal cancer) face disproportionate burdens that demand focused research and tailored solutions. Dr. Davidson flags serious headwinds: proposed cuts to NIH/NCI research funding, potential reductions in Medicaid (and knock-on effects to Medicare), and eroding trust in science—all of which could slow lifesaving progress and discourage the next generation of investigators. The call to listeners: recognize how research already touches our families, and advocate for access and sustained investment.
Dr. Davidson’s Leadership Playbook: Bridging Divides
Dr. Davidson’s leadership counsel is simple and powerful: anchor in mission (“a world without cancer”), build truly interdisciplinary teams, harmonize (not inflate) egos, and ensure everyone’s contribution is seen and credited. Pair that culture with resilience for the long game—because science advances iteratively, and patient care demands steadiness through uncertainty. Her wish for listeners: embrace the value of research—past and future—and remember that “cancer” is not synonymous with “death sentence.” Progress is real, hope is justified, and when we rally around patients and science together, we bridge divides and move closer to a world where more people live longer, healthier lives.
